Targeting tumor cells with antibodies enhances anti-tumor immunity

Zhichen Sun; Yang-Xin Fu; Hua Peng

doi:10.1007/s41048-018-0070-2

Volume 4 Issue 5

Nov. 2018

Turn off MathJax

Article Contents

Article Navigation > Biophysics Reports > 2018 > 4(5): 243-253

Zhichen Sun, Yang-Xin Fu, Hua Peng. Targeting tumor cells with antibodies enhances anti-tumor immunity[J]. Biophysics Reports, 2018, 4(5): 243-253. doi: 10.1007/s41048-018-0070-2

Citation:

Zhichen Sun, Yang-Xin Fu, Hua Peng. Targeting tumor cells with antibodies enhances anti-tumor immunity[J]. Biophysics Reports, 2018, 4(5): 243-253. doi: 10.1007/s41048-018-0070-2

Zhichen Sun, Yang-Xin Fu, Hua Peng. Targeting tumor cells with antibodies enhances anti-tumor immunity[J]. Biophysics Reports, 2018, 4(5): 243-253. doi: 10.1007/s41048-018-0070-2

Citation:

Zhichen Sun, Yang-Xin Fu, Hua Peng. Targeting tumor cells with antibodies enhances anti-tumor immunity[J]. Biophysics Reports, 2018, 4(5): 243-253. doi: 10.1007/s41048-018-0070-2

PDF (456 KB)

Targeting tumor cells with antibodies enhances anti-tumor immunity

doi: 10.1007/s41048-018-0070-2

Zhichen Sun^1,2,
Yang-Xin Fu^1,3,
Hua Peng^{1
,
,}

1 Key Laboratory of Infection and Immunity, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
2 University of Chinese Academy of Sciences, Beijing 100049, China
3 Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

Funds: Hua Peng

More Information

Corresponding author: Hua Peng
Received Date: 25 May 2018
Publish Date: 02 November 2018

Abstract

Abstract

Tumor-targeting antibodies were initially defined as a group of therapeutic monoclonal antibodies (mAb) that recognize tumor-specific membrane proteins, block cell signaling, and induce tumor-killing through Fc-driven innate immune responses. However, in the past decade, ample evidence has shown that tumor-targeting mAb (TTmAb) eradicates tumor cells via activation of cytotoxic T cells (CTLs). In this review, we specifically focus on how TTmAbs induce adaptive anti-tumor immunity and its potential in combination therapy with immune cytokines, checkpoint blockade, radiation, and enzymetargeted small molecule drugs. Exploring the mechanisms of these preclinical studies and retrospective clinical data will significantly benefit the development of highly efficient and specific TTmAb-oriented anti-tumor remedies.
- Tumor antigen,
- Targeting antibody,
- Innate immunity,
- Adaptive immunity,
- Cytokine,
- Tumor microenvironment

FullText(HTML)

References(122)

References

Abes R, Gelize E, Fridman WH, Teillaud JL (2010) Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood 116:926-934

Abramson V, Arteaga CL (2011) New strategies in HER2-overexpressing breast cancer:many combinations of targeted drugs available. Clin Cancer Res 17:952-958

Ahmadzadeh M, Rosenberg SA (2006) IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107:2409-2414

Ahn MJ, Sun JM, Lee SH, Ahn JS, Park K (2017) EGFR TKI combination with immunotherapy in non-small cell lung cancer. Expert Opin Drug Saf 16:465-469

Arteaga CL, Engelman JA (2014) ERBB receptors:from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 25:282-303

Barcellos-Hoff MH, Park C, Wright EG (2005) Radiation and the microenvironment-tumorigenesis and therapy. Nat Rev Cancer 5:867-875

Bardelli A, Siena S (2010) Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 28:1254-1261

Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA (1996) An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response.Proc Natl Acad Sci USA 93:7826-7831

Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, Man W, Peale F, Ross S, Wiesmann C, Fuh G (2009) Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323:1610-1614

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med 366:2455-2465

Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12:541-552

Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285-4289

Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J Jr, Chang HY, van de Rijn M, Shortliffe L, Weissman IL (2009) Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA 106:14016-14021

Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate nonHodgkin lymphoma. Cell 142:699-713

Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R (2011) Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71:1374-1384

Chavez AR, Buchser W, Basse PH, Liang X, Appleman LJ, Maranchie JK, Zeh H, de Vera ME, Lotze MT (2009) Pharmacologic administration of interleukin-2. Ann N Y Acad Sci 1182:14-27

Citri A, Yarden Y (2006) EGF-ERBB signalling:towards the systems level. Nat Rev Mol Cell Biol 7:505-516

Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets.Nat Med 6:443-446

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648

De Luca R, Soltermann A, Pretto F, Pemberton-Ross C, Pellegrini G, Wulhfard S, Neri D (2017) Potency-matched dual cytokineantibody fusion proteins for cancer therapy. Mol Cancer Ther 16:2442-2451

Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR (2014) STING-dependent cytosolic dna sensing promotes radiation-induced type I interferondependent antitumor immunity in immunogenic tumors.Immunity 41:843-852

Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur CD, White JM, Kalinke U, Murphy KM, Schreiber RD (2011) Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 208:1989-2003

Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7-H1 promotes T-cell apoptosis:a potential mechanism of immune evasion. Nat Med 8:793-800

Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, Jones H, Wilkinson RW, Honeychurch J, Illidge TM (2014) Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res 74:5458-5468

Du YJ, Lin ZM, Zhao YH, Feng XP, Wang CQ, Wang G, Wang CD, Shi W, Zuo JP, Li F, Wang CZ (2013) Stability of the recombinant anti-erbB2 scFv-Fc-interleukin-2 fusion protein and its inhibition of HER2-overexpressing tumor cells. Int J Oncol 42:507-516

Ennis BW, Lippman ME, Dickson RB (1991) The EGF receptor system as a target for antitumor therapy. Cancer Invest 9:553-562

Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Gine E, Durrant S, Kneissl M, Luu KT, Hua SY, Boni J, Vandendries E, Dang NH (2013) Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma:results of a phase I/Ⅱ study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. J Clin Oncol 31:573-583

Gillies SD, Lan Y, Hettmann T, Brunkhorst B, Sun Y, Mueller SO, Lo KM (2011) A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res 17:3673-3685

Gutbrodt KL, Schliemann C, Giovannoni L, Frey K, Pabst T, Klapper W, Berdel WE, Neri D (2013) Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med 5:201ra118

Gutbrodt KL, Casi G, Neri D (2014) Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice.Mol Cancer Ther 13:1772-1776

Hartimath SV, Manuelli V, Zijlma R, Signore A, Nayak TK, Freimoser-Grundschober A, Klein C, Dierckx R, de Vries EFJ (2018) Pharmacokinetic properties of radiolabeled mutant Interleukin-2v:a PET imaging study. Oncotarget 9:7162-7174

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723

Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357:39-51

Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA (2013) Phase Ⅱ randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.J Clin Oncol 31:1157-1163

Hynes NE, Lane HA (2005) ERBB receptors and cancer:the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293-12297

Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BWS, Nelson DJ (2003) IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature:a novel mechanism for IL-2. J Immunol 171:5051-5063

Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL (2009) CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138:271-285

Jensen HK, Donskov F, Nordsmark M, Marcussen N, von der Maase H (2009) Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res 15:1052-1058

Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704

Kiessling R, Wei WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K, Seliger B (2002) Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 85:101-144

Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K (2007) Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 98:1275-1280

Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS (2012) A phase Ⅱ study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30:3234-3241

Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, Patel A, Mills GB, Bast RC Jr (2005) Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 280:2092-2104

Lee Y, Chin RK, Christiansen P, Sun Y, Tumanov AV, Wang J, Chervonsky AV, Fu YX (2006) Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptordependent tertiary lymphoid structure. Immunity 25:499-509

Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:301-311

Liao W, Lin JX, Leonard WJ (2013) Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38:13-25

Liao J, Luan Y, Ren Z, Liu X, Xue D, Xu H, Sun Z, Yang K, Peng H, Fu YX (2017) Converting lymphoma cells into potent antigenpresenting cells for interferon-induced tumor regression.Cancer Immunol Res 5:560-570

Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu YX, Xu MM (2015) CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med 21:1209-1215

Lorenzi S, Mattei F, Sistigu A, Bracci L, Spadaro F, Sanchez M, Spada M, Belardelli F, Gabriele L, Schiavoni G (2011) Type I IFNs control antigen retention and survival of CD8alpha(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol 186:5142-5150

Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD (2015) Five-year survival rates for treatmentnaive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase Ⅲ trial. J Clin Oncol 33:1191-1196

Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N, Weissman IL (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138:286-299

Maloney DG (2012) Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 366:2008-2016

Maloney DG, Brown S, Czerwinski DK, Liles TM, Hart SM, Miller RA, Levy R (1992) Monoclonal anti-idiotype antibody therapy of B-cell lymphoma:the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells.Blood 80:1502-1510

Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R (1994) Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466

Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, Varns C, Rosenberg J, Levy R (1997a) IDEC-C2B8:results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266-3274

Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R (1997b) IDEC-C2B8(Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.Blood 90:2188-2195

McCracken MN, Cha AC, Weissman IL (2015) Molecular pathways:activating T cells after cancer cell phagocytosis from blockade of CD47 "Don't Eat Me" signals. Clin Cancer Res 21:3597-3601

Menard S, Pupa SM, Campiglio M, Tagliabue E (2003) Biologic and therapeutic role of HER2 in cancer. Oncogene 22:6570-6578

Meric-Bernstam F, Hung MC (2006) Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 12:6326-6330

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532-536

Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK (2010) A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene 29:3896-3907

Moasser MM (2007) Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26:6577-6592

Morgan DA, Ruscetti FW, Gallo R (1976) Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007-1008

Mortenson ED, Park S, Jiang Z, Wang S, Fu YX (2013) Effective anti-neu-initiated antitumor responses require the complex role of CD4+ T cells. Clin Cancer Res 19:1476-1486

Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A (2008) Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789-1796

Nahta R, Esteva FJ (2006) Herceptin:mechanisms of action and resistance. Cancer Lett 232:123-138

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T (2001)Autoimmune dilated cardiomyopathy in PD-1 receptordeficient mice. Science 291:319-322

O'Day SJ, Hamid O, Urba WJ (2007) Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4):a novel strategy for the treatment of melanoma and other malignancies. Cancer 110:2614-2627

Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network:receptor heterodimerization in development and cancer. EMBO J 19:3159-3167

Panelli MC, White R, Foster M, Martin B, Wang E, Smith K, Marincola FM (2004) Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med 2:17

Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252-264

Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, Liu Y, Tang J, Wang S, Fu YX (2010) The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity.Cancer Cell 18:160-170

Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241-2251

Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ (2004) Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739-749

Pestka S, Krause CD, Walter MR (2004) Interferons, interferon-like cytokines, and their receptors. Immunol Rev 202:8-32

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672

Quaglino E, Mastini C, Forni G, Cavallo F (2008) ErbB2 transgenic mice:a tool for investigation of the immune prevention and treatment of mammary carcinomas. Curr Protoc Immunol 82(1):20-29

Rajkumar T, Gullick WJ (1994) The type I growth factor receptors in human breast cancer. Breast Cancer Res Treat 29:3-9

Ren Z, Guo J, Liao J, Luan Y, Liu Z, Sun Z, Liu X, Liang Y, Peng H, Fu YX (2017) CTLA-4 limits anti-CD20-mediated tumor regression. Clin Cancer Res 23:193-203

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, ChiarionSileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015a) Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med 372:320-330

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A (2015b) Pembrolizumab versus ipilimumab in advanced melanoma.N Engl J Med 372:2521-2532

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684

Rosenberg SA (2014) IL-2:the first effective immunotherapy for human cancer. J Immunol 192:5451-5458

Rosenberg SA, Yang JC, White DE, Steinberg SM (1998) Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2:identification of the antigens mediating response. Ann Surg 228:307-319

Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, Porcedda P, Boggio K, Smorlesi A, Lollini PL, Landuzzi L, Colombo MP, Giovarelli M, Musiani P, Forni G (2000) DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165:5133-5142

Russ A, Hua AB, Montfort WR, Rahman B, Riaz IB, Khalid MU, Carew JS, Nawrocki ST, Persky D, Anwer F (2018) Blocking "don't eat me" signal of CD47-SIRPalpha in hematological malignancies, an in-depth review. Blood Rev. https://doi.org/10.1016/j.blre.2018.04.005

Scaltriti M, Baselga J (2006) The epidermal growth factor receptor pathway:a model for targeted therapy. Clin Cancer Res 12:5268-5272

Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, Patt D, Chen TT, Berman DM, Wolchok JD (2015) Pooled analysis of long-term survival data from phase Ⅱ and phase Ⅲ trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33:1889-1894

Shepard HM, Brdlik CM, Schreiber H (2008) Signal integration:a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Investig 118:3574-3581

Shin DS, Ribas A (2015) The evolution of checkpoint blockade as a cancer therapy:what's here, what's next? Curr Opin Immunol 33:23-35

Sim GC, Martin-Orozco N, Jin L, Yang Y, Wu S, Washington E, Sanders D, Lacey C, Wang Y, Vence L, Hwu P, Radvanyi L (2014) IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J Clin Investig 124:99-110

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remedios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tuting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, PenaultLlorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Preville X, Uze G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, Andre F, Kroemer G, Zitvogel L (2014) Cancer cellautonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20:1301-1309

Skrombolas D, Frelinger JG (2014) Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol 10:207-217

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science 235:177-182

Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, Teng MW, Smyth MJ (2011) Anti-ErbB-2 mAb therapy requires type I and Ⅱ interferons and synergizes with anti-PD-1 or antiCD137 mAb therapy. Proc Natl Acad Sci USA 108:7142-7147

Sunada H, Magun BE, Mendelsohn J, MacLeod CL (1986) Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation.Proc Natl Acad Sci USA 83:3825-3829

Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, Wang J, Wang X, Fu YX (2016) Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade.Cancer Cell 30:500

Tang H, Liang Y, Anders RA, Taube JM, Qiu X, Mulgaonkar A, Liu X, Harrington SM, Guo J, Xin Y, Xiong Y, Nham K, Silvers W, Hao G, Sun X, Chen M, Hannan R, Qiao J, Dong H, Peng H, Fu YX (2018) PD-L1 on host cells is essential for PD-L1 blockademediated tumor regression. J Clin Investig 128:580-588

Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, Chan C, Parren PW, Hack CE, Dechant M, Valerius T, van de Winkel JG, Glennie MJ (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104:1793-1800

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454

Trinchieri G (2010) Type I interferon:friend or foe? J Exp Med 207:2053-2063

van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB (2006) Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibodydependent cellular cytotoxicity. Clin Cancer Res 12:4027-4035

Wang Y, Zhu M, Miller M, Fu YX (2009) Immunoregulation by tumor necrosis factor superfamily member LIGHT. Immunol Rev 229:232-243

Wieduwilt MJ, Moasser MM (2008) The epidermal growth factor receptor family:biology driving targeted therapeutics. Cell Mol Life Sci 65:1566-1584

Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PO, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109:6662-6667

Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr, Grob JJ, Chesney J, Chin K, Chen K, Hoos A, O'Day SJ, Lebbe C (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma:a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11:155-164

Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber GN, Fitzgerald KA, Alegre ML, Gajewski TF (2014) STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.Immunity 41:830-842

Xuan C, Steward KK, Timmerman JM, Morrison SL (2010) Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood 115:2864-2871

Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG (2001) Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38:17-23

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM (2013a) Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Cancer Immunol Immunother 62:1303-1313

Yang X, Zhang X, Mortenson ED, Radkevich-Brown O, Wang Y, Fu YX (2013b) Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Mol Ther 21:91-100

Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, Fu YX (2014) Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 25:37-48

Yarden Y, Pines G (2012) The ERBB network:at last, cancer therapy meets systems biology. Nat Rev Cancer 12:553-563

Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137

Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Janne PA (2011) Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 3:99ra86

Yoon J, Koo KH, Choi KY (2011) MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res 71:445-453

Young KH, Baird JR, Savage T, Cottam B, Friedman D, Bambina S, Messenheimer DJ, Fox B, Newell P, Bahjat KS, Gough MJ, Crittenden MR (2016) Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy. PLoS ONE 11:e0157164

Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu YX (2004) Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 5:141-149

Yu P, Lee Y, Wang Y, Liu X, Auh S, Gajewski TF, Schreiber H, You Z, Kaynor C, Wang X, Fu YX (2007) Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 179:1960-1968

Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT, Stephan MT, Kim JS, Yaffe MB, Irvine DJ, Weiner LM, Dranoff G, Wittrup KD (2015)Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell 27:489-501

Zou W, Zheng H, He TC, Chang J, Fu YX, Fan W (2012) LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response. Cancer Res 72:2980-2989

Supplements(0)

Relative Articles

Cited By

Proportional views